Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06255054
Other study ID # ColoradoSPH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 20, 2020
Est. completion date May 2025

Study information

Verified date February 2024
Source Colorado School of Public Health
Contact Sarah A Limbacher, MPH
Phone 4406377882
Email sarah.limbacher@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Researchers at the University of Colorado Anschutz Medical Campus, Colorado School of Public Health, and Injury & Violence Prevention Center want to learn more about how people are affected by cannabis in different ways. We will use a driving simulator to compare the driving performance of adults who use cannabis daily, occasionally or have not recently used cannabis.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date May 2025
Est. primary completion date June 2024
Accepts healthy volunteers
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - The following are inclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Participants who are =21 years old and =55 years old 2. Participants who are able to provide written, informed consent 3. Participants with active healthcare coverage (including health insurance, Medicaid, etc.) 4. Participants who are willing to complete up to two in-person study visits (one for Phases 1 & 2, and two for Phases 3 & 4), including up to two urine drug screens, two alcohol breathalyzer tests, and one urine pregnancy test (if applicable) 5. Participants who agree to refrain from using non-prescription psychotropic drugs (e.g., ecstasy), hallucinogens, and synthetic cannabinoids during the study 6. Participants who agree to refrain from drinking >3 alcoholic drinks the day prior to the data collection study visit (the single visit for Phases 1 & 2, and the second visit for Phases 3 & 4) 7. Participants who agree to refrain from using any cannabis products for at least 8 hours prior to the data collection study visit (the single visit for Phases 1 & 2, and the second visit for Phases 3 & 4) 8. Participants who are willing to provide and use their own cannabis product that has been procured from a licensed dispensary, is labeled with THC potency, and contains <2% CBD (cannabis use groups only; the single visit for Phases 1 & 2, and the second visit for Phases 3 & 4) 9. Participants who agree to have a sober driver pick them up after the data collection study visit (cannabis use groups only; the single visit for Phases 1 & 2, and the second visit for Phases 3 & 4) 10. Participants who take at least 2 inhalations ("hits") during their typical inhalational (smoking/vaporizing) sessions, or ingest at least 5 mg of THC when they consume edible cannabis products (cannabis use groups only) 11. Participants who are willing to provide a sample of their cannabis to be independently tested for potency and terpene content (Phases 1, 3 & 4 only) Exclusion Criteria: - The following are exclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Prisoners 2. Participants who have nocturnal schedules (e.g., work night shifts) 3. Participants with a history of abuse or addiction to substances other than cannabis (e.g., prescription and non-prescription pharmaceuticals, alcohol, or illicit drugs) 4. Participants who have expressed an interest in substance abuse treatment within the 60 days prior to study enrollment 5. Participants who report consuming an average of >3 alcoholic drinks per day in the 30 days prior to study enrollment 6. Participants with any past or current diagnosis of schizophrenia, narcolepsy, heart disease, epilepsy, or a traumatic brain injury 7. Participants who are currently experiencing untreated bipolar disorder, major depression, sleep apnea, or other uncontrolled medical conditions as determined by the investigators (e.g., hypertension) 8. Participants with a known balance or gait disorder 9. Participants with color blindness (Phase 2 only) 10. Participants who currently wear hard contact lenses for vision correction (Phase 2 only) 11. Participants who have donated 450 mL or more of blood in the two weeks prior to study enrollment 12. Participants who are pregnant or breastfeeding (female participants only) 13. Participants who report never using cannabis before in their lifetime (Phases 1 & 2 only) 14. Participants with a history of clinically significant adverse event(s) associated with cannabis intoxication (e.g., lightheadedness, nausea, dizziness, etc., cannabis use groups only) 15. Participants with uncorrected visual acuity disorder, defined as binocular vision worse than 20/40 (Phases 2, 3 & 4 only; determined at screening) 16. Participants with a body mass index >40 kg/m2 (determined at screening) 17. Participants with a positive breath alcohol test (breathalyzer) at screening 18. Participants who are otherwise unsuitable for inclusion in the study, based on the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Driving Study Lab Denver Colorado

Sponsors (1)

Lead Sponsor Collaborator
Colorado School of Public Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Driving Impairment SDLP (standard deviation of lateral position) is measured by our Advanced NADS minisim 5 years
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity